Stay updated on VAX-24 Safety in Older Adults Clinical Trial

Sign up to get notified when there's something new on the VAX-24 Safety in Older Adults Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the VAX-24 Safety in Older Adults Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:29:11.000Z thumbnail image
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    9 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a modification in the dose levels of the 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) being evaluated in adults 65 years of age and older compared to Prevnar 20™ (PCV20) in a clinical study.
    Difference
    0.1%
    Check dated 2024-06-06T14:29:59.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, specifying requirements such as age, health condition, and willingness to complete the informed consent process.
    Difference
    27%
    Check dated 2024-05-22T21:02:42.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:28:00.000Z thumbnail image

Stay in the know with updates to VAX-24 Safety in Older Adults Clinical Trial

Enter your email address, and we'll notify you when there's something new on the VAX-24 Safety in Older Adults Clinical Trial page.